アラバマ州におけるクローン病の臨床試験
アラバマ州内の拠点で、クローン病に関する9件の研究が参加者を募集しています。
アラバマ州内の都市
公式研究テキスト（英語）
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Digestive Health Specialists /ID# 280827, Dothan
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/10/02更新 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Gastro Health, Birmingham
- East View Medical Research, Mobile
被験者募集中第4相
18歳〜80歳 · 全性別 · 2026/09/30更新 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Digestive Health Specialists /ID# 266216, Dothan
- East View Medical Research /ID# 270377, Mobile
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Digestive Health Specialists of the Southeast, Dothan
- East View Medical Research, Mobile
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07499232Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Digestive Health Specialists, Dothan
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT06937099A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Digestive Health Specialsits, Dothan
被験者募集中第4相
18歳〜70歳 · 全性別 · 2026/09/09更新 · NCT06045754A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- University of South Alabama (USA) Physicians Group, Mobile
被験者募集中第3相
2歳以上 · 全性別 · 2026/05/07更新 · NCT05442567Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- IMC Gulf Coast Gastroenterology, PC, Fairhope
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/04/27更新 · NCT06456593A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Birmingham
被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/03/12更新 · NCT07113522ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。